|Assessment process complete
|For the prophylaxis of migraine in adults who have at least four migraine days per month.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of galcanezumab (Emgality®) on the basis of the proposed price relative to currently available therapies.
The HSE has approved reimbursement following confidential price negotiations March 2022.